Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study-Reference-Cited by-同舟云学术

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

Published:2006-06 Issue:3 Volume:101 Page:436-440
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Markman Maurie,Blessing John,Rubin Stephen C.,Connor Joseph,Hanjani Parviz,Waggoner Steven

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference22 articles.

1. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms;McGuire;Ann. Intern. Med.,1989

2. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study;Thigpen;J. Clin. Oncol.,1994

3. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103;Trimble;J. Clin. Oncol.,1993

4. Second-line treatment of ovarian cancer;Markman;The Oncologist,2000

5. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer;Fennelly;J. Clin. Oncol.,1997

Cited by 200 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ecological and evolutionary dynamics to design and improve ovarian cancer treatment;Clinical and Translational Medicine;2024-08-29

2. Comparison of Weekly Paclitaxel Regimens in Recurrent Platinum-Resistant Ovarian Cancer: A Single Institution Retrospective Study;Current Oncology;2024-08-15

3. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses;BJC Reports;2024-06-20

4. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum- resistant or refractory ovarian / fallopian tube / primary peritoneal cancer (NCT03093155): updated survival and subgroup analyses;2024-05-21

5. Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options;Cells;2024-05-04